Vascular Biogenics Ltd. Stock News

Gainers Greenlane Holdings, Inc. (NASDAQ: GNLN) rose 29.8% to $0.2520 in pre-market trading. Greenlane said it has sold its stake in VIBES Holdings LLC for $5.3 million in cash. Stronghold Digital Mi

- Trial Did Not Meet Statistical Significance on Improvement in Primary Endpoints of Progression Free Survival (PFS) or Overall Survival (OS) - - Trial Did Not Meet Statistical Significance on Improve

TEL AVIV, Israel and NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficul

Vascular Biogenics Ltd. (NASDAQ:VBLT ) Q1 2022 Earnings Conference Call May 17, 2022 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors, IR Dror Harats - CEO Sam Backenroth - CFO Conference

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -8.33% and 42.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -8.33% and 42.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Kala Pharma (KALA) delivered earnings and revenue surprises of -25% and 55.81%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 127.50% and 140.95%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the st

TEL AVIV, Israel and NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for diffi

Editas (EDIT) delivered earnings and revenue surprises of 8.64% and 44.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 104% and 2.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for t

Upgrades According to Johnson Rice, the prior rating for RPC Inc (NYSE:RES) was changed from Hold to Accumulate. In the first quarter, RPC showed an EPS of $0.07, compared to $0.05 from the year-ago

Here's what you need to know about trading penny stocks on April 26th The post Hot Penny Stocks to Buy Today? 3 For Your Watchlist  appeared first on Penny Stocks to Buy, Picks, News and Information

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Protagonist's Ulcerative Colitis Study Disappoints With Higher Dose Of PN-943 Protagonist Therapeutics

Fulcrum Therapeutics, Inc. (FULC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the